Challenges we
solve for pharma
teams
Global evidence is consistent. Local markets are not. We bridge the gap — fast, compliant, expert-validated.
By Team
All
Medical Affairs
Market Access
Brand & Launch
Regional Teams
By Stage
All
Pre-Launch
Launch
Mature Brand
Any Stage
By Expertise
All
Access & Localization
Evidence Generation
Launch Support
KOL & Expert Engagement
Congress & Publications
Omnichannel Content
11 challenges shown
01
Medical Affairs
Regional
The situation
HQ sent a 200-slide global deck. Your pharma affiliate needs a 12-slide country brief by Thursday — adapted to local comparators, local treatment guidelines, and local language.
How we solve it
02
Market Access
The situation
Your global value dossier uses Comparator A. The local HTA body evaluates against Comparator B. The health economics argument doesn't hold for the local payer.
How we solve it
03
Medical Affairs
The situation
ASCO, ESMO, or ESC just closed. What changed? What do we update? MSL teams, brand teams, and medical directors all need field-ready answers within 48 hours.
How we solve it
04
Medical Affairs
The situation
You need a Delphi advisory board or expert consensus document to support a positioning claim. A traditional process takes 6 months with uncertain publication timelines.
How we solve it
05
Market Access
The situation
Real-world evidence has been collected in-market, but never synthesized into a usable HTA dossier. The data exists — the argument doesn't.
How we solve it
06
Medical Affairs
The situation
Your publication plan exists on paper. But manuscripts stall, authors don't respond, and journal submission timelines slip. By the time articles are published, they're no longer useful.
How we solve it
07
Medical Affairs
Brand & Launch
The situation
The clinical data is strong, but it's locked in 40-page PDFs nobody reads. MSLs, KOLs, payers, and internal teams all need different formats — visual abstracts, infographics, slide decks.
How we solve it
08
Medical Affairs
The situation
Hundreds of medical publications monthly in your therapeutic area. Nobody has time to monitor them all, but missing a key competitor study means a strategic blind spot.
How we solve it
09
Medical Affairs
Brand & Launch
The situation
You need a small slide deck or clinical summary based on a new publication — urgently. Large medcomms agencies aren't interested. You need a responsive partner without minimum project thresholds.
How we solve it
10
Medical Affairs
Brand & Launch
The situation
Your scientific presentations may still be strategically sound, but slide decks require ongoing updates as new evidence emerges. The same deck used repeatedly loses audience engagement.
How we solve it
11
Medical Affairs
The situation
You need to source references for a medical video, verify citations for material approval (MLR review), or fact-check a KOL presentation. Tedious, time-consuming, and essential for compliance.
How we solve it
No challenges match these filters
Try selecting different combinations or clear all filters.
AI infrastructure
AI-powered.
Expert-validated.
We built AI workflows into our daily practice — not as a marketing claim, but as the infrastructure that lets our medical experts deliver faster without cutting corners.
Research
Structured PubMed queries with narrative or table outputs
Monitoring
Weekly literature digests by drug, target, or topic
AI-Enhanced EDC
Electronic data capture with AI-assisted structuring of unstructured records
Fact-Checker
Claim verification against your source documents
AI accelerates. Our experts validate.
Every output goes through expert medical review before it reaches your team. AI handles structure and speed — we handle scientific judgement and MLR readiness.
// Query: ribociclib OS data MONALEESA 2023–24
search("ribociclib overall survival", {
years: [2023, 2024],
output: "structured_table"
})
// 847 records → 23 relevant
Processing 847 records...
Evidence Summary
MONALEESA-2 updated OS (NEJM 2023): median OS 63.9 mo vs 51.4 mo (HR 0.76, 95% CI 0.63–0.93). Benefit maintained across all pre-specified subgroups...
Ready to talk about
your brand?
your brand?
Tell us what you're working on — we respond within 24 hours.
SolveLetter · Monthly insights
From the field:
evidence & practice
Advisory Boards
What Makes an Advisory Board Truly Insightful? New Trends, Smarter Ideas, and Next-Gen Formats
An advisory board is one of the most intelligent and powerful tools in the pharma arsenal. With the right event architecture, it helps generate valuable insights and build trust within the medical community.
Jun 2025 · SolveLetter #3
Read →
Evidence Strategy
Why Do RWE and RWD Projects Face Challenges, and How Can We Avoid Them?
With evidence generation becoming a key performance indicator for many medical affairs teams, interest in RWE approaches is growing rapidly. Based on experience across a dozen projects, we’ve gathered insights that might be useful.
Apr 2025 · SolveLetter #2
Read →
KOL Engagement
How to Increase Expert (KOL) Engagement in Congresses, Conferences, and Seminars?
Expert engagement at live events is declining. We explore practical solutions and formats that drive real KOL participation and meaningful scientific dialogue.
Feb 2025 · SolveLetter #1
Read →